欧洲 · 综合新闻 · Swissinfo
Novartis’ Kisqali Cuts Death Risk 19% in Breast Cancer Study
Novartis AG’s breast cancer pill Kisqali helped patients with a common form of early-stage disease live longer, bolstering the case for its use before cancer returns.
在 Swissinfo 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.swissinfo.ch)
